Germany, June 22 -- Evonik is selling selected production assets for pharmaceutical ingredients in Hanau, Germany to the contract manufacturer ProChem Group. The transaction, which is expected to close on June 19, 2026, supports the growth strategy of Evonik's Health Care business. By acquiring the facilities, the ProChem Group will strengthen its production capabilities, enhance its technological expertise, and expand its services to pharmaceutical customers.Evonik's Health Care business is streamlining its asset footprint to focus investment and growth in its core areas of expertise. These include advanced oral and injectable drug delivery technologies and precision biosolutions such as lipids for mRNA and gene delivery, and advanced cell...